YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Pacific Biosciences of California now sits against a Fair Value estimate of US$2.40 per share, up from US$2.16, giving investors an updated anchor for how analysts see the stock's potential worth. That change comes alongside Street researc…
Pacific Biosciences of California (PACB) closed the most recent trading day at $2.30, moving -15.44% from the previous trading session. This move lagged the S&P 500's daily loss of 0.47%. Meanwhile, the Dow gained 0.1%, and the Nasdaq, a t…
Why PacBio (PACB) Stock Is Trading Up Today What Happened? Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 9.9% in the afternoon session after EpiSign Inc. and Geneyx Genomex Ltd. announced a partnership t…
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MOND…
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves. NKTR is down 19.1% at $48.97…
Why Is PacBio (PACB) Stock Soaring Today What Happened? Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 29.7% in the afternoon session after EpiSign announced the launch of EpiSign METRIC 5-base, enabling…
Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and Teleflex Check out the companies making headlines yesterday: PacBio (NASDAQ:PACB): Genomics company Pacific Biosciences of California (NASDAQ:PACB…
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.51% for the day. On the other hand, the Dow…
2 Small-Cap Stocks for Long-Term Investors and 1 Facing Headwinds Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock pri…
Pacific Biosciences of California (PACB) closed at $1.38 in the latest trading session, marking a +2.99% move from the prior day. This change outpaced the S&P 500's 1.14% gain on the day. Meanwhile, the Dow gained 0.61%, and the Nasdaq, a…
3 Cash-Burning Stocks We Approach with Caution Rapid spending isn't always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. Not all companies are…
A month has gone by since the last earnings report for Pacific Biosciences of California (PACB). Shares have added about 11.6% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive tren…
10x Genomics, Inc. TXG has surged 84% in the past three months, putting pressure on its fundamentals to keep pace with the stock. Consumables growth, Atera demand and a higher 2026 outlook provide support. Weak instrument sales, operating…
Pacific Biosciences of California, Inc. PACB, or PacBio, cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition offset improving clinical activity. The revision raises the bar for clinical adoption to show…
3 Reasons to Sell PACB and 1 Stock to Buy Instead Shareholders of PacBio would probably like to forget the past six months even happened. The stock dropped 20.5% and now trades at $1.29. This was partly due to its softer quarterly results…
Winners And Losers Of Q2: Illumina (NASDAQ:ILMN) Vs The Rest Of The Life Sciences Tools & Services Stocks Looking back on life sciences tools & services stocks' Q2 earnings, we examine this quarter's best and worst performers, including Il…
1 of Wall Street's Favorite Stocks to Own for Decades and 2 We Brush Off Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it's important to remain skeptical becaus…
Quick Read MRK and MRNA's intismeran autogene beat Keytruda alone on recurrence-free survival in Phase 3 melanoma, though no specific efficacy numbers have been released yet. BNTX surged 21% on read-across excitement, while ILMN rose 16% s…
1 Healthcare Stock to Target This Week and 2 Facing Headwinds Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and thei…
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, reported an adjusted loss per share of 14 cents for the second quarter of 2026, wider than the year-ago adjusted loss of 13 cents per share. The figure came in line w…
Earnings Call Insights: Pacific Biosciences of California (PACB) Q2 2026 MANAGEMENT VIEW * "Earlier today, we announced that I am stepping down as President and Chief Executive Officer of PacBio and that Mark Van Oene will lead the company…
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the upcoming availability of SPRQ-Nx chemistry and an accompanying software update…
The second-quarter 2026 earnings season is underway, with several companies in the Medical Dental – Supplies and Medical Services industries already releasing their numbers. According to the latest Earnings Trends report, quarterly results…
1 Russell 2000 Stock on Our Watchlist and 2 That Underwhelm The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often…
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.39, marking a +2.21% move from the previous day. The stock's change was more than the S&P 500's daily gain of 0.21%. Elsewhere, the Dow saw an upswing of…
MENLO PARK, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Canaccord Ge…
1 Small-Cap Stock Worth Investigating and 2 That Underwhelm Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have…
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.49, moving -4.49% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.79%. On the other hand, the Dow registere…
Resmed RMD has entered into a definitive agreement to sell its MatrixCare business to private equity firm Frazier Healthcare Partners. The divestiture aligns with the company's long-term strategy to sharpen its focus on higher-growth oppor…
Natera NTRA announced that its molecular residual disease (MRD) test, Signatera, received certification as a Class C device under the European Union's In Vitro Diagnostic Regulation (IVDR) for use across multiple types of cancer. Signatera…
Merit Medical Systems, Inc. MMSI is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid product performance and its continued spending on research and development, is expect…
Merit Medical Systems, Inc. MMSI is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid performance in 2025 and its continued spending on research and development (R&D), is…
West Pharmaceutical Services WST recently completed the sale and transfer of the manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie ABBV. The transaction follows the $112.5 m…
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product development. The optimism, led by strong first-quarter results, is expected to contribute further. However, concerns about…
CareDx CDNA recently completed the acquisition of Naveris, expanding its presence in high-growth specialty oncology. The company had announced the acquisition agreement in April as part of its strategy to strengthen its U.S. Precision Medi…
AMN Healthcare Services, Inc. AMN is well-poised for growth in the coming quarters, courtesy of its broad array of services. The optimism is led by strong momentum in its Managed Services Program (MSP), rising labor disruption demand and i…